March 21, 2018 / 12:04 PM / 4 months ago

BRIEF-Eiger Biopharmaceuticals Sees Phase 3 D-Livr Trial Starting In Second Half 2018​

March 21 (Reuters) - Eiger Biopharmaceuticals Inc:

* EIGER BIOPHARMACEUTICALS ANNOUNCES POSITIVE GUIDANCE FOLLOWING FDA MEETING ON HEPATITIS DELTA VIRUS REGISTRATION PROGRAM

* EIGER BIOPHARMACEUTICALS INC - ‍PHASE 3 D-LIVR TRIAL PLANNED TO INITIATE IN SECOND HALF 2018​

* EIGER BIOPHARMACEUTICALS INC - PHASE 3 D-LIVR TRIAL PLANNED TO INITIATE IN SECOND HALF 2018

* EIGER BIOPHARMACEUTICALS INC - EXPECT TO SHARE ADDITIONAL INFORMATION ON PLANNED REGISTRATION PROGRAM IN 2Q 2018

* EIGER BIOPHARMACEUTICALS - ‍LIFT ENROLLMENT PLANNED FOR 2Q 2018​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below